2008: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's: Pathogenesis, Animal Models, and Genetics II

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's: Pathogenesis, Animal Models, and Genetics II

Tuesday, October 28, 2008

1802

Disruption of TGFbeta Signalling in Dermal Fibroblasts Delays Skin Wound Healing and Reduces Fibrocyte Recruitment

1803

Activation of Toll-like Receptor Pathways and Induction of Chemokine Production in Normal Human Macrophages by a Gadolinium Containing Contrast Agent: Trigger Event in the Pathogenesis of Nephrogenic Systemic Fibrosis?

1804

Role of Epidermis in Scleroderma

1805

Negative Regulation of Nuclear Receptor PPAR-γ Expression and Activity by Transforming Growth Factor-beta (TGF-ß): Implications for Fibrosis in Scleroderma

1806

Dual Profibrotic and Antifibrotic Regulation by CCL18-Attracted T Lymphocytes in Interstitial Lung Disease

1807

The Proadhesive Phenotype of Systemic Sclerosis Skin Promotes Myeloid Cell Adhesion

1808

Junctional Adhesion Molecule-A is Abnormally Expressed in Diffuse Cutaneous Systemic Sclerosis Skin and Mediates Myeloid Cell Adhesion

1809

Syndecan-2 Is A Novel Target Of The Pro-fibrotic Factor IGFBP-3 And Contributes To The Development Of Fibrosis

1810

Arginine Vasopressin in Scleroderma: Tissue Expression, Enhanced Production by Monocytes and Modulation of Collagen, Endotheline-1, Endothelial nitric Oxide and Prostacyclin Synthases Expression Levels

1811

Modulation of Il-13 and Fli1 by Adenosine - Implications for Scleroderma

1812

IGFBP-5-Induced Fibrosis is Mediated via Caveolin-1 and the Production of Reactive Oxygen Species

1813

Modulation of Fibroblast Function and Differentiation in Systemic Sclerosis by the Green Tea Antioxidant (-)-Epigallocatechin-3-Gallate

1814

Endothelin-1 activates Mesenchymal Progenitor Cells in Scleroderma

1815

Regulation And Novel Role Of The Early Response Gene Egr-1 In Fibrosis; Implications For Scleroderma

1816

Enhanced Il-10 Production By Dendritic Cells Upon Stimulation With TLR4 Agonists In Systemic Sclerosis Potentially Drives Increased Levels Of The Pro-fibrotic Chemokine Ccl18

1817

Hyaluronan, A Component Of Extracellular Matrix, In Patients With Systemic Sclerosis: Possible Association With Immunological Abnormalities Via Toll-like Receptor Signaling

1818

Plasma Cytokine Profiles In Autoantibody Subsets Of Scleroderma

1819

Anti-inflammatory Lipid Mediator Lipoxin A₄(LXA₄) In Interstitial Lung Disease Of Patients With Systemic Sclerosis And Sclerodermal Murine Model Induced By Bleomycin

1820

Anti-fibroblast Antibodies From Systemic Sclerosis Patients Bind To α-enolase And Are Associated With Interstitial Lung Disease

1821

Identification Of Target Antigens Of Endothelial Cells Antibodies In Systemic Sclerosis And Idiopathic Pulmonary Arterial Hypertension

1822

Elevated Serum IGF-1 And IGFBP-3 Levels In Patients With Systemic Sclerosis: A Possible Role In The Development Of Fibrosis

1823

Molecular Analysis Of The Anti-fibrotic Activity Of Proteasome Inhibition

1824

Funtional And Phenotypic Heterogeneity In Cultures Of Fibroblasts From Normal And Fibrotic Tissues

See more of: ACR Abstract Submission Poster Sessions

<< Previous Session Level | Next Session Level >>